Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The approval of Imfinzi was granted based on results from ... 2 "With this approval, we can now offer immunotherapy treatment to people living with limited-stage small cell lung cancer, which ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

While immunotherapy has transformed the treatment ... At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab) as a combination regimen with its PARP ...

Imfinzi was found to be well-tolerated and ... enabling more patients to access this important immunotherapy-based regimen.” The latest decision extends the antibody’s reach, which is already ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...